Nedaplatin (Synonyms: NSC 375101) |
Catalog No.GC15786
One-Click Copy Product Info
|
Nedaplatin is a derivative of cisplatin and a DNA damage agent that can induce nephrotoxicity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 95734-82-0
Sample solution is provided at 25 µL, 10mM.
Nedaplatin is a derivative of cisplatin and a DNA damage agent that can induce nephrotoxicity [1]. Nedaplatin enters cells through various transport proteins to bind to DNA, causing DNA distortion and damaging the DNA structure, and stimulates the production of reactive oxygen species, thereby inducing cellular oxidative stress[2]. Nedaplatin has been widely used to kill the proliferation of various tumor cells and has been employed to develop combined therapies to effectively inhibit tumor growth[3].
In vitro, Nedaplatin treatment for 48 hours significantly promoted cell death in HNE1 and CNE2 cells, with IC50 values of 2.75μg/ml and 1.49μg/ml, respectively[4]. Treatment with 10μg/ml Nedaplatin for 48 hours significantly induced apoptosis in SKOV3 cells, caused cell cycle arrest, accompanied by an increase in the expression of Bax, caspase-3 and caspase-9, and a decrease in the expression of Bcl-2 and MMP-2[5]. Treatment with 20μM Nedaplatin combined with 5μM ABT-737 for 48 hours led to depolarization of the mitochondrial membrane in A549 cells, promoting the degradation of Mcl-1 protein and the release of cytochrome c[6].
In vivo, Nedaplatin treatment via a single intravenous injection at a dose of 15mg/kg significantly induced the death of 15-week-old male rats within 10 days, and caused weight loss and kidney damage in the rats[7]. A single intravenous injection of 20mg/kg dose of Nedaplatin significantly induced tumor growth in a xenograft mouse model of Ma44 cells within 12 days [8].
References:
[1] Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy[J]. Cancer management and research, 2013: 67-76.
[2] Szupryczyński K, Szefler B. Interactions of Nedaplatin with Nucleobases and Purine Alkaloids: Their Role in Cancer Therapy[J]. Biomedicines, 2025, 13(7): 1551.
[3] Su X Y, Yin H T, Li S Y, et al. Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro[J]. Asian Pacific Journal of Cancer Prevention, 2012, 13(9): 4531-4536.
[4] Liu Z, Liu J, Li L, et al. Inhibition of autophagy potentiated the antitumor effect of nedaplatin in cisplatin-resistant nasopharyngeal carcinoma cells[J]. PloS one, 2015, 10(8): e0135236.
[5] Li W, Hanfeng L, Zhengwen C, et al. Nedaplatin Induced Apoptosis in Human Ovarian Cancer Cisplatin-resistant Cell Lines in vitro and Investigated Its Mechanism[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1216-1220.
[6] Zhang C, Li Y L, Weng X, et al. Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition[J]. Oncology Letters, 2016, 12(5): 4195-4202.
[7] Uehara T, Watanabe H, Itoh F, et al. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats[J]. Archives of toxicology, 2005, 79(8): 451-460.
[8] Matsumoto M, Takeda Y, Maki H, et al. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer[J]. Japanese Journal of Cancer Research: Gann, 2001, 92(1): 51.
| Cell experiment [1]: | |
Cell lines | HNE1 cells |
Preparation Method | HNE1 cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin in a humidified incubator at 37°C and 5% CO2. HNE1 cells were plated at a density of 6×103 cells/ml in a 96-well plate with growth medium for 24h, and then were incubated with the different concentrations of Nedaplatin (0, 1.5, 3, 6, 12, and 24 μg/ml) for 48 h, and the cell viability was analyzed. |
Reaction Conditions | 0, 1.5, 3, 6, 12, and 24μg/ml; 48h |
Applications | Nedaplatin treatment significantly inhibited cell viability of HNE1 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Athymic BALB/c nude mice |
Preparation Method | Female athymic BALB/c nude mice (7-week-old) were housed in an air-conditioned room with a 12h light/dark cycle and received standard laboratory rat chow and tap water. On day 0, Ma44 cells (5×105) were implanted s.c. into the back of BALB/c nude mice. Treatment was started when the tumor volume reached 100mm3. A single intravenous injection of 20mg/kg dose of Nedaplatin. Tumor size was scored throughout the experiment. |
Dosage form | 20mg/kg for once; i.v. |
Applications | Nedaplatin treatment reduced tumor volume in mice carrying Ma44 xenograft tumors. |
References: | |
| Cas No. | 95734-82-0 | SDF | |
| Synonyms | NSC 375101 | ||
| Chemical Name | azanide;2-hydroxyacetic acid;platinum(2+) | ||
| Canonical SMILES | C(C(=O)O)O.[NH2-].[NH2-].[Pt+2] | ||
| Formula | C2H8N2O3Pt | M.Wt | 303.17 |
| Solubility | ≥ 9.8mg/mL in Water | Storage | Store at -20°C,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2985 mL | 16.4924 mL | 32.9848 mL |
| 5 mM | 659.7 μL | 3.2985 mL | 6.597 mL |
| 10 mM | 329.8 μL | 1.6492 mL | 3.2985 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)